Living donor liver transplantation: usefulness of hemostatic and prothrombotic screening in potential donors.
Bleeding and thrombosis are serious complications of living donor liver transplantation (LDLT). The aim of this paper was to describe the results of a screening for coagulation disorders, including for thrombophilic factors, in potential living liver graft donors and to evaluate thrombotic and bleeding events in donors and recipients, during and after the procedure. From January 2001 to January 2007, 41 LDLTs were performed at our institution. We performed systematic screening for bleeding or prothrombotic states among 188 potential donors, 38 (20.2%) of whom showed at least one abnormality. We rejected potential donors with factor V Leiden, prothrombin mutation G20210A, and deficiencies in anticoagulant proteins (protein C, protein S, and antithrombin) or coagulation factors. Bleeding and thrombotic events in donors and recipients of the 41 LDLTs were evaluated during 7 days to 70 months follow-up. No major bleeding events were detected in the donors. Neither donor nor recipient experienced venous thrombosis or pulmonary embolism. Among all recipients, six suffered hepatic artery thrombosis including five in the first month probably related to surgery. Deep venous thrombosis and pulmonary embolism are well-known complications of hepatic surgery; Prothrombotic abnormalities in the donor can be transmitted to the recipient, leading to increased risk of serious postoperative events. Although the cost-effectiveness is not definitely established, we recommend systematic screening for hemostatic and prothrombotic disorders to prevent more morbidity of a procedure that already has high risks of bleeding and thrombosis.
Bustelos
R
R
Department of Hematology, Hospital 12 de Octubre, Madrid, Spain.
Ayala
R
R
Martinez
J
J
Martin
M A
MA
Toledo
T
T
Grande
S
S
Garfia
C
C
Moreno
A
A
Perez
B
B
Meneu
J C
JC
Moreno
E
E
Ribera
C
C
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D002675:Child, Preschool; D017984:Enoxaparin / Q000627:therapeutic use; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006490:Hemostatics; D006801:Humans; D007223:Infant; D016031:Liver Transplantation / Q000502:physiology*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D018579:Patient Selection; D010976:Platelet Count; D011486:Protein C / Q000378:metabolism; D011516:Prothrombin / Q000032:analysis*; D013923:Thromboembolism / Q000601:surgery; D019851:Thrombophilia / Q000097:blood / Q000235:genetics; D055815:Young Adult
D000925:Anticoagulants; D017984:Enoxaparin; D006490:Hemostatics; D011486:Protein C; D011516:Prothrombin; D005340:Fibrinogen